期刊文献+

结直肠癌靶向治疗的应用及前景 被引量:6

下载PDF
导出
摘要 随着结直肠癌病例发病率增高,全球每年新发病例超过100万例^[1]。目前对结直肠癌的治疗措施不断改进,除传统的手术、放疗、化疗3种主要治疗手段外,近年出现了被誉为第4种手段的分子靶向治疗,尤其是对于晚期结直肠癌总体疗效较差的情况下,
出处 《实用肿瘤杂志》 CAS 2013年第1期10-14,共5页 Journal of Practical Oncology
  • 相关文献

二级参考文献7

  • 1van Cutsem E,Peeters M,Siena S,et al.Open-label,randomized,phase 3 clinical trial of Panitumumab plus best supportive care versus best supportive cave in patients with chemotherapy-refractory metastatic colorectal cancer[J].J Clin Oncol,2007,25:1658-1664.
  • 2Berlin J,Posey J,Tchekmedyian S,et al.Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for first-line treatment of metastatic colorectal cancer[J].Clin Colorectal Cancer,2007,6:427-432.
  • 3Amado RG,Wolf M,Peeters M,et al.Wildtype KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer[J].J Clin Oncal,2008,26:1626-1634.
  • 4Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for metastatic colorectal cancer[J].N Engl J Med,2004,350:2335-2342.
  • 5Giantonio BJ,Catalano PJ,Meropol NJ,et al.Bevacizumab in combination with Oxaliplatin,Fluorouracil,and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:Results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25:1539-1544.
  • 6Saltz LB,Lenz HJ,Kindler HL,et al.Randomized phase Ⅱ trial of Cetuximab,Bevacizumab,and Irinotecan compared with Cetuximab and Bevacizumab alone in Irinotecan-refractory colorectal cancer:The BOND-2 study[J].J Clin Oncol,2007,25:4557-4561.
  • 7Tol J,Koopman M,Cats A,et al.Chemotherapy,Bevacizumab,and Cetuximab in metastatic colorectal cancer[J].N Engl J Med,2009,360:563-572.

共引文献23

同被引文献53

  • 1李凡,韩琤波,马洁韬,吴红.结直肠癌原发灶和转移灶KRAS基因状态比较的Meta分析[J].中华临床医师杂志(电子版),2011,5(13):3834-3838. 被引量:3
  • 2Michael M, Zalcberg J, (,ibbs P, et al. A phase l trial of imatinib ill combination ith mFOI.FOX6-1)evacizumab in patienls ith advanced colorectal cant!er [ J ]. Cancel' Chemolher Pharmacol, 2013,71 ( 2 ) :321 - 330.
  • 3Duereux M, A(lenis A, Pignon JP, et al. Effic;:wv and safely of bevaeizumal)-l)ased combination regimens in palients with previously unlrealt,l rnelastali,t: eoh)recla] cancer: final results ti'om a randomised phase II study of l)evaeizumab plus 5-fluorouraeil, letwoorin plus irinoteean ersus bevaeizumab plus capeeitabine plus irilotecan ( FNCLCC ACCOR1) 13/0503 tudv) [ J ]. EurJ Cancer, 2013,49(6) :1236 - 1245.
  • 4Varol U, Oktay E, Yildi6m M, et al. Tumor chara('teristics and metastatic sites may predict bevaeizumab efficacy in the firsl-line treatnmnt of metastatic eoloreetal eancer[J]. Mol Clin ()neol, 2014,2 (1):166-170.
  • 5Von Minekwilz G, Loibl S, Unteh M, et al. Survival after neoadjuvant chemotherapy with or without I)evacizmual) or everolimus tr HER2-negalive primary breast cancer ( GBG 44-GeparQuinto) dagger [J] . AnnOnc'ol, 2014,25 ( 12 ) : 2363 - 2372.
  • 6Stein A, Glockzin G, Wienke A, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature [J]. BMC Cancer, 2012,12:356.
  • 7Loupakis F, Glockzin G, Wienke A, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J]. N Engl J ned, 2014,371 (17): 1609 - 1618.
  • 8Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies [ J ]. Oncologist, 2012, 17 (8) :1039 - 1050.
  • 9Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer [ J ]. PLoS One, 2013,8(10) :e77117.
  • 10Yang F, Tang X, Riquelme E, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy [ J ]. Cancer Res, 2011,71 (16) :5512 - 5521.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部